Abstracts tagged "extraarticular manifestations"

Abstract Number: 1532 • 2015 ACR/ARHP Annual Meeting
Occurrence of Valvular Heart Disease in Rheumatoid Arthritis: A Population Based Study
Tamanna Khullar¹, John P. Bois¹, Cynthia S. Crowson², Megan L. Krause³ and Rekha Mankad¹, ¹Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of cardiovascular disease, particularly atherosclerosis and heart failure. However, little is known…
Abstract Number: 1562 • 2015 ACR/ARHP Annual Meeting
Clinical Correlates, Outcomes and Predictors of Episcleritis and Scleritis Associated with Rheumatoid Arthritis
Cristian Caimmi¹, Wendy M. Smith², Cynthia S. Crowson³, Eric L. Matteson⁴ and Ashima Makol⁵, ¹Unit of Rheumatology, Department of Medicine,, University of Verona, Verona, Italy, ²Department of Ophthalmology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
Background/Purpose: Inflammatory ocular disease (IOD) has traditionally been regarded as a severe extra-articular manifestation of rheumatoid arthritis (RA) with high mortality. This study aims to…
Abstract Number: 2500 • 2013 ACR/ARHP Annual Meeting
Mast Cells Are a Major Source Of IL-17 In Synovium and Extra-Articular Tissues In Spondyloarthritis Related Diseases
T. Noordenbos¹, I. Gofita¹, M. Alsina², E.W.M. Vogels³, A. A. te Velde³, J. D. Cañete⁴, Dominique L. Baeten⁵ and N. Yeremenko¹, ¹Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ²Department of Dermatology, Hospital Clinic de Barcelona, Barcelona, Spain, ³Tytgat Institute for Liver and Intestinal Research, Academic Medical Centre/University of Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴Rheumatology, Hospital Clinic, Barcelona, Spain, ⁵Department of Clinical Immunology and Rheumatology Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: IL-17 plays a key role in the pathogenesis of spondyloarthritis (SpA) as demonstrated by a recent proof-of-concept trial with the anti-IL17A mAb secukinumab. The…
Abstract Number: 2475 • 2013 ACR/ARHP Annual Meeting
Relationship Between Extra-Articular Manifestations and Disease Activity In Patients Diagnosed With New-Onset Spondyloarthropathy In a Cohort In Spain
César Antonio Egües Dubuc¹, Maria Martin Martinez², Joaquin Belzunegui Otano¹, Miren Uriarte Ecenarro¹, Juan Mulero³, Eugenio de Miguel⁴, Santiago Muñoz⁵, Pedro Zarco⁶, Eduardo Collantes⁷, Sabina Perez Vicente² and Milena Gobbo², ¹Rheumatology, Donostia University Hospital, San Sebastián, Spain, ²Research Unit, Spanish Society of Rheumatology., Madrid, Spain, ³Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Spain, ⁴Rheumatology, University Hospital La Paz - IdiPaz, Madrid, Spain, ⁵Rheumatology, Hospital Infanta Sofia, Madrid, Spain, ⁶Rheumatology Service, Fundación Hospital Alcorcon, Alcorcon, Madrid, Spain, ⁷Rheumatology, Hospital Reina Sofia, Cordoba, Spain
Background/Purpose : The Spondyloarthropathy (SpA) that affect in many aspects of life of the patients, either for their musculoskeletal or extra-articular manifestations (EAM). EAM vary…
Abstract Number: 345 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Peri-Articular Manifestations (Enthesitis and Dactylitis) and Disease Activity In Psoriatic Arthritis Patients: Impact Of Treatment With TNF Inhibitors In a Real-World Canadian Population
Proton Rahman¹, Denis Choquette², William G. Bensen³, Majed M. Khraishi⁴, Isabelle Fortin⁵, Andrew Chow⁶, Maqbool K. Sheriff⁷, Julie Vaillancourt⁸, John S. Sampalis⁸, Susan M. Otawa⁹, Allen J. Lehman⁹ and May Shawi¹⁰, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁴Nexus Clinical Research, St John's, NF, Canada, ⁵Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁶University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: To determine the point prevalence of peri-articular manifestations (PAMs) in psoriatic arthritis (PsA) patients treated with anti-TNF in a real-world, Canadian, routine clinical practice…
Abstract Number: 1552 • 2012 ACR/ARHP Annual Meeting
Clinical Correlates, Treatment Outcomes and Predictors of Vasculitis Associated with Rheumatoid Arthritis in the ‘Biologic Era’ : A Case-Control Study
Ashima Makol¹, Cynthia S. Crowson², Eric L. Matteson³ and Kenneth J. Warrington¹, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: 1.To determine the clinical presentation, treatment and outcomes of vasculitis (RV) associated with rheumatoid arthritis (RA) in the era of biologic use. 2. To…
Abstract Number: 1217 • 2012 ACR/ARHP Annual Meeting
Decreased Survival in Rheumatoid Arthritis Complicated with Bronchiectasis: A Family-Based Cohort Study
Xavier Puéchal¹, Emmanuelle Génin², Thierry Bienvenu³ and Daniel J. Dusser⁴, ¹National Referral Center for Rare Systemic Auto-immune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ²Biostatistics, INSERM UMR-S946, Université Paris Diderot, Paris, France, ³Biochemistry and Molecular Biology, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ⁴Respiratory Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
Background/Purpose: In cystic fibrosis, mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene lead to diffuse bronchiectasis (DB) and decreased survival. DB is also…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].